# Inhibition of Complement Will Substantially Reduce the Anemia of Malaria

## TL;DR

Complement inhibition could reduce anemia caused by malaria by preventing the destruction of healthy red blood cells.

## Contribution

The paper proposes using FDA-approved complement inhibitors to treat malarial anemia by blocking C3b opsonization.

## Key findings

- Complement activation leads to the clearance of nonparasitized erythrocytes in malaria.
- FDA-approved drugs can inhibit complement at the C3b opsonization step for several days.
- In vitro studies are needed to test if complement inhibitors prevent C3 activation on healthy red blood cells.

## Abstract

There is compelling evidence that complement plays a major role in the elimination of nonparasitized erythrocytes (np‐Es) in the anemia of malaria. In fact, for every erythrocyte destroyed after infection by Plasmodium falciparum (Pf) or Plasmodium vivax, at least 10 np‐Es are cleared, most likely due to C3b opsonization. In malaria, complement is activated by three breakdown products released from lysed parasitized erythrocytes (p‐Es): hemin/hematin, the digestive vacuole (DV), and hemozoin. Both childhood anemia in malaria and post‐artesunate delayed‐hemolysis in individuals with malaria treated with artesunate can be ascribed to complement activation. These findings are important with respect to development of potential therapies for malarial anemia because there are now available FDA‐approved drugs that completely inhibit complement at the C3 activation step for several days at a time. We review key clinical findings and basic science investigations that implicate complement and in particular C3b opsonization as a significant factor in malarial anemia. Extension of these basic science studies to examine FDA‐approved drugs that block complement at the C3b opsonization step are needed to justify their potential utilization in treatment of malarial anemia. In particular, in vitro studies in blood cultures of Pf/vivax should determine whether deposition of C3 activation products on np‐Es can be completely prevented in the presence of complement inhibitors. If these experiments validate proof of concept, then extension of this paradigm to a clinical trial based on combined treatment with artesunate plus an FDA‐approved complement inhibitor would be indicated.